Article Details

Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing

Retrieved on: 2021-03-31 13:52:30

Tags for this article:

Click the tags to see associated articles and topics

Scribe Therapeutics Closes Series B Round With $100M To Target Gene Editing. View article details on hiswai:

Excerpt

Meanwhile, Vijay Pande, general partner at Andreessen Horowitz, said in a statement that Scribe's approach has “revolutionized industry expectations ...

Article found on: news.crunchbase.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo